AgomAb Therapeutics (NASDAQ:AGMB) Stock Price Down 6.3% – Here’s What Happened

Shares of AgomAb Therapeutics NV (NASDAQ:AGMB) traded down 6.3% during trading on Thursday . The company traded as low as $14.00 and last traded at $14.0150. Approximately 59,191 shares were traded during mid-day trading, a decline of 56% from the average session volume of 134,962 shares. The stock had previously closed at $14.96.

Analyst Ratings Changes

A number of research firms have recently issued reports on AGMB. Cantor Fitzgerald began coverage on AgomAb Therapeutics in a research report on Wednesday, August 19th. They set an “overweight” rating on the stock. HC Wainwright began coverage on AgomAb Therapeutics in a research report on Monday, June 22nd. They issued a “buy” rating and a $35.00 target price for the company. Wall Street Zen downgraded shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. B. Riley Financial started coverage on shares of AgomAb Therapeutics in a report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price target on the stock. Finally, Piper Sandler started coverage on shares of AgomAb Therapeutics in a research note on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $37.50.

AgomAb Therapeutics Stock Down 6.1%

The firm has a 50 day moving average price of $13.41 and a two-hundred day moving average price of $12.51.

AgomAb Therapeutics (NASDAQ:AGMB) last posted its earnings results on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. On average, sell-side analysts predict that AgomAb Therapeutics NV will post -1.76 earnings per share for the current year.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.